COSCIENS Biopharma Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.6M | $7.1M | $14.6M | $5.3M | $3.7M | $532.0K | $26.9M |
| Cost of Revenue | $4.9M | $4.9M | $4.2M | $6.0M | $90.0K | $2.3M | $410.0K | $2.1M |
| Gross Profit | $2.6M | $4.7M | $2.9M | $8.6M | $5.2M | $1.3M | $122.0K | $24.8M |
| Gross Margin | 35.3% | 49.3% | 41.1% | 58.7% | 98.3% | 36.6% | 22.9% | 92.2% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — |
| Operating Income | $-10.7M | $-18.3M | $-4.6M | $4.3M | $-8.7M | $-5.7M | $-10.2M | $9.8M |
| Operating Margin | -142.5% | -190.7% | -64.8% | 29.6% | -164.8% | -156.2% | -1,925.2% | 36.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-10.3M | $-15.2M | $-4.4M | $4.5M | $-8.5M | $-4.7M | $-6.2M | $9.6M |
| Income Tax Expense | $10.0K | $84.0K | $-885.0K | $1.1M | $-109.0K | $395.0K | $-188.0K | $5.5M |
| Net Income | $-10.4M | $-15.3M | $-3.5M | $3.4M | $-8.4M | $-5.1M | $-6.0M | $4.2M |
| Net Margin | -138.1% | -159.7% | -48.8% | 23.7% | -159.1% | -140.1% | -1,135.7% | 15.6% |
| EPS (Basic) | $-3.27 | $-5.93 | $-1.89 | $1.87 | $-1.82 | $-3.11 | $-0.35 | $0.25 |
| EPS (Diluted) | $-3.27 | $-5.93 | $-1.89 | $1.86 | $-1.82 | $-3.11 | $-0.35 | $0.24 |
| Shares Outstanding (Basic) | 3.2M | 3.1M | 4.9M | 4.9M | 121.4M | 62.7M | 20.0M | 16.4M |
| Shares Outstanding (Diluted) | 3.2M | 3.1M | 4.9M | 4.9M | 121.4M | 62.7M | 20.0M | 16.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |